IDEXX Laboratories (NASDAQ:IDXX) Reaches New 12-Month Low After Insider Selling

IDEXX Laboratories, Inc. (NASDAQ:IDXX) hit a new 52-week low during mid-day trading on Wednesday after an insider sold shares in the company. The stock traded as low as $515.86 and last traded at $519.3270, with a volume of 24987 shares traded. The stock had previously closed at $520.21.

Specifically, Director Lawrence D. Kingsley sold 2,203 shares of the stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $532.08, for a total value of $1,172,172.24. Following the completion of the sale, the director directly owned 9,568 shares of the company’s stock, valued at approximately $5,090,941.44. This represents a 18.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Analyst Ratings Changes

IDXX has been the topic of a number of research reports. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, August 27th. Citigroup increased their target price on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. UBS Group boosted their price target on IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Finally, Barclays reduced their price objective on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research report on Tuesday, August 11th. Six research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $747.00.

IDEXX Laboratories Stock Performance

The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. The firm has a market cap of $39.90 billion, a P/E ratio of 35.62, a PEG ratio of 2.75 and a beta of 1.54. The stock’s 50 day moving average is $556.66 and its two-hundred day moving average is $566.88.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, topping analysts’ consensus estimates of $3.94 by $0.33. The firm had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The company’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter last year, the company earned $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, equities analysts predict that IDEXX Laboratories, Inc. will post 14.81 EPS for the current year.

Hedge Funds Weigh In On IDEXX Laboratories

Hedge funds and other institutional investors have recently modified their holdings of the stock. Empowered Funds LLC lifted its holdings in shares of IDEXX Laboratories by 6.6% during the first quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock valued at $646,000 after acquiring an additional 95 shares during the period. Sivia Capital Partners LLC acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter worth about $265,000. Jump Financial LLC lifted its holdings in IDEXX Laboratories by 1,006.4% during the 2nd quarter. Jump Financial LLC now owns 5,532 shares of the company’s stock valued at $2,967,000 after purchasing an additional 5,032 shares during the last quarter. Cary Street Partners Financial LLC bought a new position in IDEXX Laboratories during the 2nd quarter valued at about $164,000. Finally, Sei Investments Co. boosted its position in IDEXX Laboratories by 218.7% in the second quarter. Sei Investments Co. now owns 120,587 shares of the company’s stock valued at $64,678,000 after buying an additional 82,755 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops and provides diagnostic, information technology and veterinary practice-management products and services. The company primarily serves the companion animal, livestock and poultry, and water testing markets, helping customers detect, monitor and manage disease.

Its companion animal business includes in-house laboratory analyzers and consumables, reference laboratory services, diagnostic tests, veterinary software, digital imaging and related practice-management solutions.